摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

pyrazole-1-carboxylic acid benzyl ester | 219580-34-4

中文名称
——
中文别名
——
英文名称
pyrazole-1-carboxylic acid benzyl ester
英文别名
1-benzyloxycarbonylpyrazole;benzyl 1H-pyrazole-1-carboxylate;benzyl pyrazole-1-carboxylate
pyrazole-1-carboxylic acid benzyl ester化学式
CAS
219580-34-4
化学式
C11H10N2O2
mdl
——
分子量
202.213
InChiKey
VCOVXPNYFAUGFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    343.9±35.0 °C(Predicted)
  • 密度:
    1.17±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    pyrazole-1-carboxylic acid benzyl ester四(三苯基膦)钯正丁基锂potassium carbonate 作用下, 以 四氢呋喃 为溶剂, 反应 25.35h, 生成 C15H12N4O2
    参考文献:
    名称:
    Organometallic compound and organic light-emitting device including the same
    摘要:
    公开号:
    EP2706064B1
  • 作为产物:
    描述:
    吡唑氯甲酸苄酯 在 sodium hydride 作用下, 以 二氯甲烷 为溶剂, 反应 4.5h, 以85%的产率得到pyrazole-1-carboxylic acid benzyl ester
    参考文献:
    名称:
    Organometallic compounds and organic light emitting devices including the same
    摘要:
    提供了包括有机金属化合物和含有这些金属化合物的有机发光器件。每种有机金属化合物可能是一个过渡金属配合物,包括最多七个有机配体,其中包括一个到三个配体是2-(吡唑-3-基)嘧啶和2-(1,2,4-三唑-3-基)嘧啶之一的衍生物。包括这些有机金属化合物的有机发光器件显示出比包括比较性有机金属配合物的有机发光器件更低的驱动电压、更高的亮度、更高的效率和更好的寿命特性。
    公开号:
    US09595683B2
点击查看最新优质反应信息

文献信息

  • Organometallic compounds and organic light emitting devices including the same
    申请人:Samsung Display Co., Ltd.
    公开号:US09595683B2
    公开(公告)日:2017-03-14
    Organometallic compounds and organic light-emitting devices including the same are provided. Each subject organometallic compound may be a transition metal complex comprising up to seven organic ligands including one to three ligands which are derivatives of one of 2-(pyrazole-3-yl)pyrimidine and 2-(1,2,4-triazol-3-yl)pyrimidine. Organic light-emitting devices including the subject organometallic compounds show lower driving voltages, higher luminences, higher efficiencies and better lifetime characteristics versus organic light-emitting devices including comparative organometallic complexes.
    提供了包括有机金属化合物和含有这些金属化合物的有机发光器件。每种有机金属化合物可能是一个过渡金属配合物,包括最多七个有机配体,其中包括一个到三个配体是2-(吡唑-3-基)嘧啶和2-(1,2,4-三唑-3-基)嘧啶之一的衍生物。包括这些有机金属化合物的有机发光器件显示出比包括比较性有机金属配合物的有机发光器件更低的驱动电压、更高的亮度、更高的效率和更好的寿命特性。
  • NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
    申请人:MEIJI SEIKA PHARMA CO., LTD.
    公开号:US20150141401A1
    公开(公告)日:2015-05-21
    A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC 1-6 alkyl; C represents benzyl, H or SO 3 M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C 1-6 alkyl or acyl; Rc represents C 1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C 1-6 alkyl, O═, or Rg-(CH 2 ) 0-3 —, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO 2 S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C 1-6 alkyl or MO—; Re and Rf represent H or C 1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.
    这是一种二氮杂双环辛烷化合物,是一种β-内酰胺酶抑制剂,化学式为(I),其中A代表Ra(Rb)N—或RcO—;B代表NH或NC1-6烷基;C代表苄基、氢或SO3M,其中M代表氢、无机或有机阳离子;Ra和Rb代表氢、C1-6烷基或酰基;Rc代表C1-6烷基或杂环基;A未被取代或被0至4个取代基Fn1取代,其中Fn1代表C1-6烷基、O═或Rg-(CH2)0-3—,其中Rg代表杂环基、苯基、杂环芳基、酰基、RdO2S—、Re(Rf)N—、Re(Rf)NCO—、ReO—、ReOCO—或保护基,其中Rd代表C1-6烷基或MO—;Re和Rf代表氢或C1-6烷基,Ra和Rb之间、Rc和B之间或Re和Rf之间可以形成至少一个含有氮原子的杂环。
  • BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
    申请人:MEIJI SEIKA PHARMA CO., LTD.
    公开号:US20160024090A1
    公开(公告)日:2016-01-28
    A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC 1-6 alkyl; C represents benzyl, H or SO 3 M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C 1-6 alkyl or acyl; Rc represents C 1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C 1-6 alkyl, O═, or Rg-(CH 2 ) 0-3 —, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO 2 S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C 1-6 alkyl or MO—; Re and Rf represent H or C 1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.
    一种二氮杂双环辛烷化合物,其为β-内酰胺酶抑制剂,由以下式子(I)表示:其中,A代表Ra(Rb)N-或RcO-;B代表NH或NC1-6烷基;C代表苄基、H或SO3M,其中M代表H、无机或有机阳离子;Ra和Rb代表H、C1-6烷基或酰基;Rc代表C1-6烷基或杂环基;A未被取代或被0至4个Fn1取代,其中Fn1代表C1-6烷基、O═或Rg-(CH2)0-3-,其中Rg代表杂环基、苯基、杂环芳基、酰基、RdO2S-、Re(Rf)N-、Re(Rf)NCO-、ReO-、ReOCO-或保护基,其中Rd代表C1-6烷基或MO-;Re和Rf代表H或C1-6烷基,Ra和Rb之间、Rc和B之间或Re和Rf之间可以形成至少一个含有氮原子的杂环。
  • Beta-lactamase inhibitor and process for preparing the same
    申请人:MEIJI SEIKA PHARMA CO., LTD.
    公开号:US10023573B2
    公开(公告)日:2018-07-17
    A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.
    一种制备下式(I)所代表的重氮双环辛烷化合物的工艺: 其中A代表RcO-;B代表NH或NC1-6烷基;C代表苄基;Rc代表C1-6烷基;A被一个取代基Fn1取代,其中Fn1代表氮杂环丁烷基团;该工艺包括:(a)将下式(IV-c)代表的化合物硅烷化: 其中,在式 (IV-c) 中,OBn 代表苄氧基,以及 (b) 进行分子内脲形成反应。
  • Processes for preparing a diazabicyclooctane compound
    申请人:MEIJI SEIKA PHARMA CO., LTD.
    公开号:US10556905B2
    公开(公告)日:2020-02-11
    A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.
    一种制备下式(I)所代表的重氮双环辛烷化合物的工艺: 其中A代表RcO-;B代表NH或NC1-6烷基;C代表苄基;Rc代表C1-6烷基;A被一个取代基Fn1取代,其中Fn1代表氮杂环丁烷基团;该工艺包括:(a)将下式(IV-c)代表的化合物硅烷化: 其中,在式 (IV-c) 中,OBn 代表苄氧基,以及 (b) 进行分子内脲形成反应。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐